Patanjali Ayurved

Indian multinational conglomerate company

Follow Patanjali Ayurved on Notably News to receive short updates to your email — rarely!

2024 Advertisement and sales promotion expenses increased by 145.46% to Rs 424.7 crore, demonstrating aggressive marketing and expansion strategy.
August 2024 Supreme Court closed contempt proceedings against Patanjali Ayurved co-founders Baba Ramdev and Acharya Balkrishna, accepting their apology after they took steps to rectify their mistakes, while warning them to comply with future orders.
February 2024 Supreme Court imposed a temporary ban on Patanjali's advertisements and issued a contempt notice to the company and its managing director Balkrishna, directing them to publish apologies in newspapers.
2023 Advertisement and sales promotion expenses were Rs 173.13 crore.
November 2023 Supreme Court cautioned Patanjali against misleading advertisements and threatened a fine of Rs 1 crore per product for deceptive claims.
May 2023 A Delhi-based law firm issued a legal notice to Patanjali Ayurved, accusing the company of using 'cuttlefish bones' in a dental care product and falsely marketing it as a vegetarian product, which allegedly violates legal standards for product labeling.
August 2022 Indian Medical Association filed a petition accusing Patanjali of disparaging allopathy and violating the Drugs and Other Magical Remedies Act, 1954 and the Consumer Protection Act, 2019.
August 2022 Newslaundry published a report alleging that Patanjali Ayurved forcibly took control of Dalits' lands in Teliwala village, Uttarkhand for establishing cow shelters and herb farms, effectively rendering local Dalits landless and forcing them to either work for the company or migrate for employment.
2021 Company achieves record revenue of ₹59,318 crores, solidifying its position as a major player in the Indian consumer goods market
May 2021 Balkrishna, the co-founder and majority shareholder (owning 94% of the company), reached a significant net worth milestone.
May 22 2021 Indian Medical Association (IMA) in Uttarakhand sent a defamation notice to Patanjali Ayurved.
February 2021 Patanjali Ayurveda CEO Balkrishna admitted on Twitter that their Coronil approvals were from the Drugs Controller General of India for export purposes, not as a certification of COVID-19 treatment effectiveness.
February 22 2021 The World Health Organization (WHO) publicly stated that it had not reviewed or certified any traditional medicine for COVID-19 treatment, directly contradicting Patanjali's claims.
2020 Patanjali Ayurved reaches ₹48,456 crores in revenue, potentially benefiting from increased health product demand during the COVID-19 pandemic
June 2020 The government of Maharashtra banned Coronil in the state, with home minister Anil Deshmukh threatening legal action against Patanjali Ayurved.
June 2020 Patanjali Ayurved announced Coronil, a purported COVID-19 treatment drug, claiming it could cure the disease, despite having no clinical data to prove its effectiveness or safety.
June 2020 The Ministry of AYUSH issued a statement denying authorization for Coronil and asking the company to stop selling and advertising the drug until trial results were examined.
2019 Company experiences massive revenue jump to ₹30,000 crores, demonstrating significant market penetration
December 2019 Patanjali acquired the bankrupt Ruchi Soya Industries in a significant business expansion move.
2018 The Maharashtra government initiated a probe into the Divya Putrajeevak Seed drug to investigate potential legal violations, with Congress leaders demanding a ban on the product.
November 2018 Patanjali Ayurved opened Patanjali Paridhan, a clothing store in Delhi, expanding their business into retail apparel.
January 2018 Villages in Haridwar district complained about Patanjali's Padarth factory polluting Ganges channels and local water bodies, with surface runoff reportedly killing several animals. Local residents from 40 villages threatened agitation over the environmental damage.
January 2018 The Uttarakhand Environment Conservation and Pollution Control Board ordered a clean-up of waste flowing through the area around Patanjali's Padarth factory, following previous notifications about untreated industrial effluent releases.
September 2017 Delhi High Court ordered Patanjali to stop airing an advertisement for chyavanprash that disparaged a competitor's product.
2016 A report by India Infoline (IIFL) highlighted that Patanjali's success was expected to affect at least 13 listed companies, including major consumer goods brands like Hindustan Unilever, Colgate, Dabur, ITC, and Godrej Consumer Products.
2016 Patanjali Food and Herbal Park was granted security from 35 full-time, armed Central Industrial Security Force (CISF) commandos, becoming the eighth private institute in India to receive such paramilitary protection.
2016 Recognized by CLSA and HSBC as one of the fastest-growing Fast-Moving Consumer Goods (FMCG) companies in India.
2016 The Uttarakhand health department declared that the Divya Putrajeevak Seed drug violated the Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994.
2016 Patanjali Ayurved estimated its annual turnover for the 2016–17 fiscal year, indicating significant business growth and market impact.
July 2016 End of the period where 33 complaints were received against 21 misleading advertisements, with seventeen violating ASCI advertising standards.
May 2016 The company reached nearly 4,700 retail outlets nationwide, significantly expanding its retail presence.
2015 Dramatic revenue surge to ₹8,000 crores, indicating rapid expansion of Patanjali Ayurved's business
2015 Patanjali's mustard oil was found to be substandard by the FSSAI's Alwar laboratory in Rajasthan, raising concerns about the company's product quality.
November 15 2015 Patanjali introduced its instant noodles, which subsequently received a notice from the Food Safety and Standards Authority of India (FSSAI) for lacking necessary manufacturing approvals.
October 9 2015 Patanjali Ayurved joined Pittie Group and Kishore Biyani's Future Group, expanding product distribution to Future Group outlets.
July 2015 The issue of Divya Putrajeevak Seed was raised in the Indian Parliament, with opposition members accusing Ramdev of selling a product that promised the birth of male children.
April 2015 First period of receiving complaints about misleading advertisements, with 33 complaints received against 21 advertisements between April 2015 and July 2016.
2014 Significant revenue growth reaches ₹2,006 crores, marking a substantial increase in the company's financial performance
2010 Patanjali Ayurved reports initial revenue of ₹1,000 crores for the financial year 2010-11

This contents of the box above is based on material from the Wikipedia article Patanjali Ayurved, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.

See Also